Option 10: B cell Depleting Agents
B cell depleting agents, such as rituximab, are another class of biologic medications used to treat RA. These drugs work by targeting and reducing the number of B cells, which are immune cells that play a role in the inflammation and joint damage associated with RA.
Rituximab is typically administered through intravenous infusion and is often used in combination with methotrexate in patients who have not responded adequately to other DMARDs or TNF inhibitors. This medication has been shown to reduce inflammation, slow joint damage, and improve overall function in people with RA.
As with other biologic medications, there is an increased risk of infections and other side effects when using B cell depleting agents. Regular monitoring and communication with your healthcare team are essential to ensure the medication is working effectively and safely. If you experience any side effects or have concerns about your treatment, it’s important to discuss them with your healthcare provider, as adjustments to your treatment plan may be necessary. (10)
